RecruitingPhase 2NCT07021794

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

Effectiveness of Treating Post-COVID-19 Conditions (Long COVID) With the SARS-CoV-2 Specific Monoclonal Antibody, Sipavibart

Sponsor

Nancy Klimas

Enrollment

100 participants

Start Date

Jun 16, 2025

Study Type

INTERVENTIONAL

Conditions

Post-COVID / Long-COVID

Summary

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a biological treatment called Sipavibart for people with post-covid / long-covid. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

A single dose of placebo (saline) indistinguishable from the active drug in appearance

BIOLOGICALSipavibart

A single intramuscular dose of Sipavibart, 300 mg

Locations(1)

Nova Southeastern University

Fort Lauderdale, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07021794

Related Trials

Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

NCT070139031 location